Shaolin Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Shaolin Capital Management’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-550,000	Closed	-$5.76M	–	587
2026 Q1	$5.76M	Buy	550,000 +347,931	+172%	+$3.63M	0.21%	59
2025 Q4	$2.1M	Buy	202,069 +52,069	+35%	+$538K	0.06%	179
2025 Q3	$1.54M	Buy	150,000 +50,000	+50%	+$513K	0.07%	153
2025 Q2	$1.02M	Buy	+100,000	New	+$1.01M	0.04%	133

Other funds holding DMAA

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return

SAMU

SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Shaolin Capital Management's DMAA Position: Q2 2026 in Review

Shaolin Capital Management sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 550,000 shares — an estimated $5.76M sold.

Shaolin Capital Management first reported a position in DMAA in Q2 2025 and held it in 4 quarters. The position peaked at $5.76M in Q1 2026. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Shaolin Capital Management reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
Shaolin Capital Management sold 550,000 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $5.76M.
Shaolin Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and held it in 4 quarters.
Shaolin Capital Management's Drugs Made In America Acquisition Corp position peaked at $5.76M in Q1 2026.
18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Shaolin Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.